Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To explore the impact of KRAS, NRAS and BRAF mutations as well as KRAS mutation variants in patients with metastatic colorectal cancer (mCRC) receiving first-line therapy. PATIENTS AND METHODS: A total of 1239 patients from five randomized trials (FIRE-1, FIRE-3, AIOKRK0207, AIOKRK0604, RO91) were included into the analysis. Outcome was evaluated by the Kaplan-Meier method, log-rank tests and Cox models. RESULTS: In 664 tumors, no mutation was detected, 462 tumors were diagnosed with KRAS-, 39 patients with NRAS- and 74 patients with BRAF-mutation. Mutations in KRAS were associated with inferior progression-free survival (PFS) and overall survival (OS) [multivariate hazard ratio (HR) for PFS: 1.20 (1.02-1.42), P = 0.03; multivariate HR for OS: 1.41 (1.17-1.70), P < 0.001]. BRAF mutation was also associated with inferior PFS [multivariate HR: 2.19 (1.59-3.02), P < 0.001] and OS [multivariate HR: 2.99 (2.10-4.25), P < 0.001]. Among specific KRAS mutation variants, the KRAS G12C-variant (n = 28) correlated with inferior OS compared with unmutated tumors [multivariate HR 2.26 (1.25-4.1), P = 0.001]. A similar trend for OS was seen in the KRAS G13D-variant [n = 71, multivariate HR 1.46 (0.96-2.22), P = 0.10]. More frequent KRAS exon 2 variants like G12D [n = 152, multivariate HR 1.17 (0.86-1.6), P = 0.81] and G12V [n = 92, multivariate HR 1.27 (0.87-1.86), P = 0.57] did not have significant impact on OS. CONCLUSION: Mutations in KRAS and BRAF were associated with inferior PFS and OS of mCRC patients compared with patients with non-mutated tumors. KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D (trend) being associated with rather poor survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Approximately 45% of patients diagnosed with mCRC have KRAS mutations, and the presence of mutations is important both in terms of prognosis [9,10].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [9]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, the KRAS p.G12C mutation is associated with poorer prognosis in terms of progression-free survival (PFS) and overall survival (OS) compared to other KRAS mutations as well as KRAS wild-type tumors.4-7”
From Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A pooled analysis by the Arbeitsgemeinschaft Internistische Onkologie [AIO] study group revealed that KRAS G12C mutation was significantly associated with lower OS compared with tumors with no KRAS mutations [16]”
From The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study (2021) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“Patients with other KRASm, including KRAS G12A/D/S/V and KRAS G13D, had OS times ranging from 17.6 to 25.2 months.51”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [51]
In the citing paper
“A post hoc analysis of pooled clinical data from 1239 patients from 5 randomized trials, in which patients with mCRC were treated with chemotherapy with or without bevacizumab as first-line treatment (67%), reported that patients harboring KRAS G12C had the shortest median OS (16.8 [95% CI: 15.6, 18.0] months).51”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [51]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 3×
“Despite the limitation of sample size in single trials, BRAF mutation represents a consistently poor prognostic marker in the context of mCRC treatment [1, 11, 12], associated with rapid clinical deterioration after progression to initial therapy [12].”
BackgroundDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · cited 2×
“Despite the limitation of sample size in single trials, BRAF mutation represents a consistently poor prognostic marker in the context of mCRC treatment [1, 11, 12], associated with rapid clinical deterioration after progression to initial therapy [12].”
BackgroundHeinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740 · cited 1×
“patients andmethods studies This analysis is based on individual patient data from five first-line trials in mCRC: FIRE-1 [14, 15], FIRE-3 (only bevacizumab-arm) [2, 16, 17], AIO KRK 0604 [18], AIO KRK 0207 [19] and RO91 [20].”
MethodSelf-citationCremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092 · cited 3×
“well with recent reports of first-line treatment in mCRC [5, 24].”
BackgroundResultVan Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Self-citationBokemeyer, C., Bondarenko, I., Hartmann, J. T., de Braud, F., Schuch, G., Zubel, A., Celik, I., Schlichting, M., & Koralewski, P. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq632 · Cited by 775
De Roock, W., Jonker, D. J., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., et al. (2010) · JAMA · doi:10.1001/jama.2010.1535 · Cited by 748
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Research works printed but not linked: 1
- 19. Stintzing S, Jung A, Rossius L, Modest DP et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3 A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer patients. In ESMO/ECCO, 2013; Abstract E17-7073.
Cited by
Items 301–351 of 351
Alig, A. H. S., Modest, D. P., Stintzing, S., Heinrich, K., Geißler, M., von Weikersthal, L. F., Decker, T. W., Vehling‐Kaiser, U., Held, S., Moosmann, N., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4673673
Self-citationPrognostic and Predictive Factors in Metastatic Colorectal Cancer
Österlund, E. (2024) · doi:10.33063/diva-522642
Molecular Biomarkers in Colorectal Cancer in the Era of Precision Medicine: A Review
Colombo, A., Gebbia, V., Borsellino, N., & Porretto, C. M. (2024) · International Journal of Advanced Multidisciplinary Research and Studies · doi:10.62225/2583049x.2024.4.3.2738
KRAS p.G12C mutation in metastatic colorectal cancer
Oncology Unit C.D.C Macchiarella – Palermo, I., Colombo, A., Porretto, C. M., & Oncology Unit C.D.C Macchiarella – Palermo, I. (2023) · Open Journal of Clinical and Medical Case Reports · doi:10.52768/2379-1039/2140
Molecular characteristics of left-sided, advanced stage colorectal cancer: A Mexican perspective
José, L.-T. M., Martínez‐Benítez, B., Jean, M.-N., Rafae, M. G., & González, M. G. J. D. A. (2024) · doi:10.52768/jjgastro/1190
Wang, M., Zhu, P., Shi, Y., Sun, Q.-M., & Dong, W.-H. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i25.5805
Vitali, F., Merkel, S., Schubart, C., Schmid, A., Eckstein, M., Stöhr, R., Kersting, S., Hartmann, A., Grützmann, R., & Wein, A. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001636
Zhang, Y., Guan, H., Liu, S., Li, H., Bian, Z., He, J., Zhao, Z., Qiu, S., Mo, T., Zhang, X., et al. (2025) · eLife · doi:10.7554/elife.103559.3
DETERMINING THE BRAND AND MODEL OF A CAR FROM THE FRONT END PHOTO USING NEURAL NETWORKS
Zhuro, D., & Tsykarev, A. (2024) · Practice Oriented Science: UAE – Russia – India · doi:10.34660/inf.2023.46.36.040
Frolovskaia, A. V., Klinduch, N. Y., & Terekhova, I. I. (2024) · Practice Oriented Science: UAE – Russia – India · doi:10.34660/inf.2023.83.66.038
DAMAGE TO THE MAXILLOFACIAL REGION BY BURKITT’S LYMPHOMA
Zakharova, P. V., Alieva, S. I., & Ibrokhimova, P. N. (2024) · Practice Oriented Science: UAE – Russia – India · doi:10.34660/inf.2023.90.71.036
Tashilova, A. A. (2024) · Practice Oriented Science: UAE – Russia – India · doi:10.34660/inf.2023.36.77.042
Sadreeva, S. K. S., & Зинатуллина, Д. С. (2024) · Practice Oriented Science: UAE – Russia – India · doi:10.34660/inf.2023.46.55.031
Григорьевна, Б. А., Suslov, K. V., & Ma, S. (2024) · Practice Oriented Science: UAE – Russia – India · doi:10.34660/inf.2023.69.43.029
NEOLOGISMS IN AUTOMOTIVE DISCOURSE
Bondareva, S. E. (2024) · Practice Oriented Science: UAE – Russia – India · doi:10.34660/inf.2023.13.77.018
Grishin, V. A., Ovchinnikova, E. G., Михайловна, М. П., & Kolesnikova, Е. А. (2024) · Practice Oriented Science: UAE – Russia – India · doi:10.34660/inf.2023.32.79.034
Шахуд, А. (2024) · Practice Oriented Science: UAE – Russia – India · doi:10.34660/inf.2023.29.68.017
Chursina, A., Агаев, Р. А. О., & Станкевичуте, Е. (2024) · Practice Oriented Science: UAE – Russia – India · doi:10.34660/inf.2023.26.13.016
IVAN IVANVYSHNEGRADSKY AND HIS MICROTONAL MUSIC
Gladkova, O. (2024) · Practice Oriented Science: UAE – Russia – India · doi:10.34660/inf.2023.63.19.024
Mosienko, T. A., & Максимович, М. М. (2024) · Practice Oriented Science: UAE – Russia – India · doi:10.34660/inf.2023.54.12.013
THE IMPACT OF THE COVID-19 PANDEMIC ON THE PHYSICAL DEVELOPMENT OF SCHOOL-AGE CHILDREN
Нугманова, А. М., Krykbaeva, A. R., & Yessengali, N. M. (2024) · Practice Oriented Science: UAE – Russia – India · doi:10.34660/inf.2023.48.53.027
INTERPERSONAL CONFLICT AS A FORM OF COMMUNICATION
Romanova, E. S., & Rychikhina, E. N. (2024) · Practice Oriented Science: UAE – Russia – India · doi:10.34660/inf.2023.17.96.019
Zhang, Y., Guan, H., Liu, S., Li, H., Bian, Z., He, J., Zhao, Z., Qiu, S., Mo, T., Zhang, X., et al. (2025) · eLife · doi:10.7554/elife.103559.1
Actualización del cáncer colorrectal
Martínez, B. M.-A., Alfonso, A. L., Poveda, M. D., & Villaverde, R. M. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.01.012 · Cited by 1
Chang, C., Liang, Y., Lin, B., Chen, K., & Yeh, K. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00609 · Cited by 2
Microbiota-based modulation of intratumoral cholesterol metabolism for colorectal cancer treatment
Wu, J., Lai, Y., Li, J., Li, J., Asthana, P., Zhai, L., Chen, M., Chen, B., Chen, B., Gurung, S., et al. (2026) · Nature Metabolism · doi:10.1101/2025.05.02.651972
Zhang, Y., Guan, H., Liu, S., Li, H., Bian, Z., He, J., Zhao, Z., Qiu, S., Mo, T., Zhang, X., et al. (2025) · eLife · doi:10.7554/elife.103559.2
Krebs, E., Weymann, D., Lim, H. J., Yip, S. S. F., & Regier, D. A. (2025) · Health Services Research · doi:10.1111/1475-6773.70009 · Cited by 1
Kakizaki, F., Miyoshi, H., Yamamoto, T., Morimoto, T., Matsubara, H., Kitano, S., Yamaura, T., Maekawa, H., Brown, J. B., Sato, T. S., et al. (2025) · Cancer Science · doi:10.1111/cas.70235
Onur, İ. D., Doğan, M., Öztürk, M. A., Şahin, T. K., Kiracı, M., Arslan, A. M., Agitoğlu, E. K., Karaoğlan, B. B., Majidova, N., Şahin, E., et al. (2025) · Current Oncology · doi:10.3390/curroncol32110639 · Cited by 1
Liu, X., Ou, K., Ma, X., Gao, L., Wang, Q., Zhang, H., & Yang, L. (2022) · Figshare · doi:10.6084/m9.figshare.20356381
Fang, X., Zhong, C., Weng, S., 胡涵光, Wang, J., Xiao, Q., Wang, J., Sun, L., Xu, D., Liao, X., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23706899
Hsieh, M.-C., Rau, K., Liu, K.-W., Chiu, C., Chen, C., Song, L., & Chen, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-36509-y
Zhao, Q., Zhao, K., Song, J., & Zhao, W. (2026) · BMC Cancer · doi:10.1186/s12885-026-15740-w
Molecular Mechanisms of Liver Metastasis: Connecting Biology, Biomarkers, and Outcomes
Wagner, D., Balzer, F., & Margonis, G. A. (2026) · Cells · doi:10.3390/cells15050469
Sayed, M. E., Harati, M. E., Shealy, M. W., & Youssef, S. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01439-5 · Cited by 1
Kanemitsu, K., Hayashi, H., Tagayasu, Y., Tanizaki, T., Adach, Y., Ofuchi, T., Tajiri, T., Kitano, Y., Okabe, H., & Iwatsuki, M. (2026) · Research Square · doi:10.21203/rs.3.rs-9008145/v1
Su, X., Si, Y., Huang, W., Zhao, H., Leong, S., Zhang, Y., Wu, Y., Xiu, X., & Song, P. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c06785 · Cited by 2
Colorectal Micropapillary Adenocarcinoma: Molecular Mechanisms and Clinical Implications
Chen, B., Zhang, R., Ding, Y., Zhang, K., Song, X., & Chen, J. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01372-z
Formica, V., Morelli, C., Rofei, M., Calegari, M. A., Riondino, S., Pace, G. D., Divizia, A., Cenci, T., Trovato, G., Orlandi, A., et al. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01445-7
Samaille, T., Raeisi, M., Cohen, R., Shi, Q., Yoshino, T., Zalcberg, J. R., Adams, R., Cremolini, C., Grothey, A. F., Mayer, R. J., et al. (2026) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2026.05.007
Kanemitsu, K., Hayashi, H., Tagayasu, Y., Tanizaki, T., Adachi, Y., Ofuchi, T., Tajiri, T., Kitano, Y., Okabe, H., & Iwatsuki, M. (2026) · Surgery Today · doi:10.1007/s00595-026-03377-y
Rahnama, Y., Shahbazi, A., Dadashi, A., Fathabadi, F. F., Salahshour, F., Delazar, S., Sedaghat, M., Keshvari, A., Kazemeini, A., Keramati, M. R., et al. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01522-x
Doermann, A. S., Caspi, A., Evans, A. E., Feci, A., Entezari, A. A., Snook, A. E., & Waldman, S. A. (2026) · Cancer Biology & Therapy · doi:10.1080/15384047.2026.2683096 · Cited by 1
Maker, A. V., Li, M., Newhook, T. E., Dulundu, E., Tanabe, K. K., Day, R., Vauthey, J., & Hallet, J. I. (2026) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2026.102541
Çokgezer, S., Sakar, B., & Karabulut, S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166279
Xie, J., Wang, S., Liu, J., Zhang, Y., Zhu, H., Cui, R., Yao, Y., Yu, W., & Hou, P. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02429-5
Kit, O. I., Mironenko, I. N., Dzhenkova, E. A., Gevorkyan, Y. A., Soldatkina, N. V., Maslov, A. A., Fomenko, I. A., Petrov, D. S., & Vladimirova, L. Y. (2026) · South Russian Journal of Cancer · doi:10.37748/2686-9039-2026-7-3-1
Morita, R., Norikane, T., Yamamoto, Y., Manabe, Y., Murao, M., Obata, T., Mitamura, K., Okuyama, H., & Nishiyama, Y. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187113
Veen, T., Lea, D., Balto, A., Edland, K. H., Kanani, A., & Søreide, K. (2026) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2026.112178
Kerkhoff, T. M. E., Hamers, P. A. H., Koopman, M., Kok, N. F. M., Lemmens, V. E., de Hingh, I., & van Erning, F. N. (2026) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2026.112307
Metadata
- Authors
- Modest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., Giessen-Jung, C., Stahler, A., Schmoll, H. J., Jung, A., Kirchner, T., Tannapfel, A., & Reinacher-Schick, A.
- Affiliations
- German Cancer Research Center (DE)
- Ludwig-Maximilians-Universität München (DE)
- Universitätsklinikum Knappschaftskrankenhaus Bochum (DE)
- Kliniken Maria Hilf (DE)
- LMU Klinikum (DE)
- University Hospital in Halle (DE)
- Ruhr University Bochum (DE)
- Corresponding author
- Modest, D.P.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 27
- Issue
- 9
- Pages
- 1746-1753
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC4999563
- OpenAlex
- W2465450966
- Semantic Scholar
- c6c03496c35c248a5905726558f97863fff59b9b
- Cited by
- 351
- References
- 31
- Citations by year
- 2026: 25 · 2025: 48 · 2024: 63 · 2023: 50 · 2022: 33 · 2021: 39 · 2020: 40 · 2019: 20 · 2018: 15 · 2017: 15 · 2016: 2
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor, 1160 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, KRAS mutation, NRAS mutation, BRAF mutation, KRAS G12C, KRAS G13D, first-line therapy, progression-free survival, overall survival, predictive biomarkers, prognostic factors
- MeSH terms
- Female, Humans, Male, Membrane Proteins, Mutation, Neoplasm Metastasis, Colorectal Neoplasms, Randomized Controlled Trials as Topic, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Disease-Free Survival, GTP Phosphohydrolases, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.